#ESC25: Ionis’ study success in moderately high triglyceride levels raises the curtain for pivotal readout in severe diseasenews2025-08-30T14:45:51+00:00August 30th, 2025|Endpoints News|
#ESC25: Alnylam to kick off CV events trial of zilebesiran despite mid-stage blood pressure missnews2025-08-30T14:30:24+00:00August 30th, 2025|Endpoints News|
#ESC25: AstraZeneca aims for 2025 filing with ‘best-in-class’ hypertension pillnews2025-08-30T14:15:52+00:00August 30th, 2025|Endpoints News|
Turbulence at the CDC; How Scripps reinvented its financial model; Biopharma’s return to MC4R; and morenews2025-08-30T10:00:18+00:00August 30th, 2025|Endpoints News|
#ESC25: Cytokinetics says heart drug data could change standard of carenews2025-08-30T07:18:35+00:00August 30th, 2025|Endpoints News|
FDA approves BTK inhibitor that’s key to Sanofi’s immunology strategynews2025-08-29T22:01:01+00:00August 29th, 2025|Endpoints News|
FDA approves Eisai and Biogen’s subcutaneous Leqembinews2025-08-29T21:00:40+00:00August 29th, 2025|Endpoints News|
FTC and congressional oversight leader take aim at PBMs againnews2025-08-29T17:56:02+00:00August 29th, 2025|Endpoints News|
Lilly terminates two Phase 2 studies of next-gen oral GLP-1 drugnews2025-08-29T17:47:06+00:00August 29th, 2025|Endpoints News|
Patient Square raises $3.1B in interim close, as health investor seeks more for second fundnews2025-08-29T14:57:31+00:00August 29th, 2025|Endpoints News|
